Precision Medicine in Oncology®

Outcomes were significantly better in clinical trials that utilized a biomarker-based treatment selection strategy compared with non-personalized approaches.

Mark A. Rubin, MD, professor of Pathology and Laboratory Medicine, vice chairman for Experimental Pathology, director, Translational Research Laboratory Services, Weill Cornell Medicine and New-York Presbyterian, discusses the advantages of whole-exome sequencing and how it compares with targeted sequencing.

Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.

Raju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.